The financing secured will drive growth and accelerate commercial expansion efforts, support the scaling of commercial teams and outreach initiatives to bring CeQur Simplicity™, its 4-day wearable insulin delivery device, to more healthcare providers and patients managing diabetes. CeQur®, a medical device company dedicated to simplifying insulin delivery for individuals on multiple daily injections, today […]
Recent Posts
- June, 2026CeQur® Closes $100 Million Series E, Backed by Commercial Momentum and Growing Demand for CeQur Simplicity™
- CeQur® Announces Exciting Advancements: 2 Recent FDA Clearances and New Clinical Evidence to be Presented at ADA
- June, 2025CeQur® Marks 10 Million Mealtime Injections Replaced and Highlights Commercial Expansion
- January, 2025CeQur Closes a $120M Equity Financing to Drive Commercial Growth
- June, 2024CeQur Simplicity™, a Wearable Mealtime Insulin Delivery Device, Obtains FDA-Clearance for 4 Days of Wear to Further Simplify Diabetes Management